The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...
A STAT examination shows how AI-powered biotechs like Absci and Generate Biomedicines routinely aggrandize their AI ...
Eli Lilly & Co. tapped the US investment-grade bond market on Monday to help finance its roughly $2.5 billion purchase of a ...
1d
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...
Grace Therapeutics intends to use the upfront net proceeds from the private placement for general corporate purposes and to fund pre-commercial development of GTx-104, a clinical stage, novel, ...
There is not a single member of AAM who has not raised concerns about the tariff situation,” said the CEO of the generic drug ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
As global markets continue to react positively to the Trump administration's recent policy changes, U.S. stocks are reaching record highs, fueled by optimism over potential trade deals and increased ...
Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...
Granules strengthens ADHD portfolio with US FDA approval for lisdexamfetamine dimesylate capsules: Our Bureau, Bengaluru Thursday, January 30, 2025, 16:15 Hrs [IST] Granules India ...
Hyderabad: Granules India Limited, a vertically integrated Indian pharmaceutical company, has announced that its wholly-owned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback